Shehroz M.’s Post

Daiichi Sankyo released an analysis of an observational study they funded that looked at people with high and very high #cardiovascularrisk in Europe. The study found that women in Europe are less likely than men to receive lipid-lowering therapies and achieve LDL cholesterol goals. These treatment inequalities suggest that women in this region are disproportionately undertreated for cardiovascular disease risk. Daiichi has reaffirmed its commitment to addressing unmet needs and #cardiovascular care barriers. Learn more: https://hubs.la/Q02NrY9W0 #cvd #cardiovasculardisease #cholesterol #healthequity #daiichisankyo

MASH (Metabolic dysfunction–associated steatohepatitis) is very common in those with type 2 diabetes and we have limited tools to address the advancing fibrosis and ultimate risk of cirrhosis. Here very promising that tirzepatide (known as Mounjaro or Zepbound) resulted in resolution of MASH without worsening of fibrosis in more than half of patients. #liverDisease #diabetes American Diabetes Association #tirzepatide #Glp1

Important MASH data for tirzepatide. I’m going to update our Essential Guide to Prescription Drugs publication on this!

🧠 Exciting News! 🧠 The FDA has just approved Lilly’s Kisunla™ (donanemab-azbt) for treating early symptomatic Alzheimer’s disease! This groundbreaking treatment has shown incredible results, slowing cognitive and functional decline by up to 35% and significantly reducing the risk of disease progression. Kisunla is a game-changer in Alzheimer’s treatment with its innovative approach to targeting amyloid plaques and offering a limited-duration treatment regimen. Nearly half of the study participants completed their course of treatment in just 12 months! 🌟 Key Highlights: • Up to 35% slower cognitive and functional decline • Reduced risk of disease progression by up to 39% • 84% average reduction in amyloid plaques This brings new hope to millions affected by Alzheimer’s disease. For more details, check out the link below! 👇 https://lnkd.in/gYPznzmB #Alzheimers #AlzheimersAwareness #MedicalResearch #FDAApproval #Kisunla #Donanemab #Lilly #Hope #Health #Innovation

Endometriosis Awareness Month NIH released a media brief today noting new future studies of a medication previously prescribed for arthritis pain. Fenoprofen, a nonsteroidal anti-inflammatory drug (NSAID), was selected from a "computer algorithm to evaluate nearly 1,300 existing compounds..."  for further study in a rodent model of endometriosis. Well, it's a case of starting somewhere, even if only to help symptom management. The brief includes acknowledgement that "many existing treatments have challenging side effects, do not treat the source of the disease and leave a chance for recurrence. To help address these issues, NICHD recently launched the Advancing Cures and Therapies and ending ENDOmetriosis diagnostic delays (ACT ENDO) initiative." Read the press release here: https://lnkd.in/eXz9WxiV #endometriosisawareness #endendo #womenshealthmatters #healthandwellness

Semaglutide strikes again! At this point, maybe we should add it to the water supply! 🤔💧This new research on its potential to reduce Alzheimer’s risk in patients with type 2 diabetes is especially compelling. This study from Case Western Reserve analyzed a vast database and found significantly lower Alzheimer’s rates among patients on semaglutide compared to those using other diabetes medications. Semaglutide works by targeting GLP-1 receptors to regulate blood sugar and appetite, and now, we’re seeing hints that it may also offer neuroprotective effects. While these findings are encouraging, it’s essential to proceed with randomized clinical trials to establish causation. But if future studies confirm semaglutide’s protective role, it could have tremendous implications for Alzheimer’s prevention, particularly among those with type 2 diabetes, who face a heightened risk. This is definitely worth watching as we delve deeper into the connections between metabolic health and cognitive decline. #SemaglutideBenefits #AlzheimersPrevention #MetabolicHealth #CognitiveHealth #DiabetesResearch #NeuroProtection #HealthInnovation #MedicalBreakthrough #FutureOfHealth https://lnkd.in/gyCEnvrz

Key opinion leaders (KOLs) interviewed by GlobalData highlight unmet needs in the kidney disease space, emphasizing the demand for next-generation therapies with alternate mechanisms of action. Ozempic, if approved, will be the first GLP-1 therapy option for patients with T2D and CKD. Learn more about how Ozempic can benefit CKD patients: #Healthcare #KidneyDisease #GlobalData #Ozempic #T2D #CKD

Today is World #MASH Day Do you know what that is? Who it may affect? Do you have any awareness of the key symptoms of this progressive disease? It is silent and slow until it is NOT? MASH is often associated with overweight, high blood lipids, and high blood sugar, and is especially prevalent in people with metabolic disorders such as type 2 diabetes and obesity. It can affect anyone, including all ages and races. Robert Gabbay MD, PhD thank you for sharing the promising news that #Tirzepatide is showing such promise, for this disease. See below to learn more!

#hypertension #bloodpressure #drugsafety #healthcare https://lnkd.in/gxqHZPjs Key Points Question Is there a difference in the long-term risk of #mortality and #morbidity outcomes for adults with #hypertension starting 1 of 3 antihypertensive treatments: thiazide-type diuretic, calcium channel blocker, or angiotensin-converting enzyme (ACE) inhibitor? Findings In this prespecified secondary analysis of outcomes of 32 804 participants in a randomized clinical trial and posttrial up to 23 years later, there was no significant difference in mortality due to cardiovascular disease among the 3 antihypertensive treatment groups. However, there was an increased risk of stroke outcomes for ACE inhibitors compared with diuretics; after accounting for multiple comparisons, this increased risk was no longer significant. Meaning Long-term follow-up supports the main findings that the diuretic group had similar cardiovascular outcomes and the ACE inhibitor group had higher stroke mortality risk.

New Hope for Pulmonary Arterial Hypertension: Promising Results with Seralutinib #Pulmonary #arterial #hypertension (PAH) is a serious condition that leads to high blood pressure in the lungs, often resulting in heart failure. Although treatment options have improved, only about half of PAH patients survive more than seven years post-diagnosis. Recent research led by Prof. Dr. Ardeschir Ghofrani from the Deutsches Zentrum für Lungenforschung (DZL) tested the new drug #Seralutinib in a Phase II study across 40 hospitals. Participants inhaled Seralutinib twice daily for 24 weeks, alongside their standard therapy. Results showed significant reductions in vascular resistance, particularly in patients with more severe symptoms, indicating Seralutinib's effectiveness in advanced stages of the disease. The drug works by inhibiting an enzyme that contributes to blood vessel remodeling in the lungs. While most participants tolerated the treatment well, common side effects included cough and elevated liver enzymes. A Phase III study for Seralutinib began in December 2023 and is set to conclude by October 2025, offering hope for improved PAH management and patient outcomes. #DZL #DZG #PulmonaryResearch #LungDisease #Science #PulmonaryHypertension #PAH #Seralutinib #ClinicalTrials #LungHealth #MedicalResearch #PatientCare #HealthInnovation